ReviewACS pharmacology & translational science2026
Engineered Cell Membrane-Coated Nanoparticles: A New Strategy for Pancreatic Cancer Therapy.
Review in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with a poor prognosis, and its treatment faces multiple challenges such as difficulties in diagnosis, a dense tumor microenvironment, and chemotherapy resistance. Cell membrane-coated nanoparticles, as a biomimetic delivery strategy, significantly enhance the circulation time and tumor accumulation efficiency of drugs by utilizing natural cell membranes to achieve immune evasion and active targeting, which holds promising potential for improving the diagnostic and therapeutic challenges of PDAC. This review systematically introduces the membrane sources, preparation, and characterization methods of cell membrane-coated nanoparticles, and elaborates on membrane functionalization strategies, including physical, chemical, and genetic engineering approaches, in enhancing targeting capabilities and enabling synergistic therapies. Furthermore, this review summarizes the specific applications of cell membrane-coated nanoparticles in improving chemotherapy resistance, synergizing with physical therapies, and remodeling the immune microenvironment for PDAC treatment. Although cell membrane-coated nanoparticles demonstrate significant potential, their clinical translation still faces challenges related to standardization and safety, which require interdisciplinary research to overcome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.